Piramal Enterprises Limited ('PEL', NSE: PEL, BSE: 500302) today announced that it has signed a definitive agreement to sell its clinical research division known as 'Piramal Clinical Research (PCR)' (formerly known as Wellquest), to Indoco Remedies Limited (Indoco) on a going concern basis for cash.
Piramal Fund Management had announced its intention to enter the construction finance space in Q3 FY15. Today, it announces that has approved 9 construction finance proposals totalling INR1100cr.
Revenue growth across businesses driving strong profitability In both the quarter and nine-month periods, the company delivered a robust financial performance with significant increase in operating profit and net profit, primarily driven by growth in revenues across all business segments.
Mumbai
Piramal Enterprises Limited ('PEL', NSE: PEL, BSE: 500302) today announced that it is in final stages of discussion with the University of Kentucky
Piramal Enterprises' Pharma Solution division, a global leader in contract development and manufacturing (CDMO), was a big winner in the recent CMO Leadership Awards.
Revenues for Q2FY2015 were higher by 10.1% at` 1,245Crores. Operating profit for Q2FY2015 was higher by 40.1% at`212 Crores. PAT was impacted by one time write down sand costs related to scaling back of NCE operations during the quarter amounting to`374Crores.
Piramal Enterprises' Pharma Solutions Division, a global pharmaceutical contract development and manufacturing organization(CDMO), has received CMO Leadership Awards 2013 in two categories-Quality and Reliability.
Piramal Imaging today announced that data from its beta-amyloid PET tracer NeuraceqTM clinical trial will be featured as part of Emerging Science sessions at the 66th American Academy of Neurology Annual Meeting at the Pennsylvania Convention Center Philadelphia, Penn.
Satisfied Users & 
Approved Press Releases
